Genenta’s series C marks start of Qianzhan’s European push

In the latest show of support for European biotech by Chinese investors, Genenta raised €13.2 million in a series C round that marks the first investment in the region by Shanghai’s Qianzhan Investment Management.

Qianzhan and Fidim, the office of the Rovati family, led the round, with two more new investors, the

Read the full 523 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE